文献速递临床免疫质量管理与危急值

新型ACMIA与QMS法检测依维莫司与LC-MS/MS的可互换性评估

Evaluation of the interchangeability between the new fully-automated affinity chrome-mediated immunoassay (ACMIA) and the Quantitative Microsphere System (QMS) with a CE-IVD-certified LC-MS/MS assay for therapeutic drug monitoring of everolimus after solid organ transplantation.
PubMed 文献 · Clin Chem Lab Med · 2022-11-04

该研究纳入67例实体器官移植患者全血样本(肾移植31例、肝移植36例),评估Siemens ACMIA/EVRO与Thermo Fisher QMS/EVER两种免疫法与CE-IVD认证LC-MS/MS检测依维莫司的可互换性。ACMIA/EVRO与LC-MS/MS存在显著比例偏差(斜率1.511,合并偏差44.8%),而QMS/EVER无显著偏差(斜率0.971,合并偏差-3.6%)。结论认为仅QMS/EVER与LC-MS/MS具有可互换性,ACMIA/EVRO因校准品赋值未充分校正代谢物交叉反应而缺乏可互换性。

要点

  • QMS/EVER与LC-MS/MS无系统及比例偏差,合并偏差-3.6%(95%CI -8.4至1.1%),具可互换性。
  • ACMIA/EVRO与LC-MS/MS存在显著比例偏差(斜率1.511,95%CI 1.420至1.619)及合并偏差44.8%(95%CI 41.2至48.3%)。
  • ACMIA/EVRO校准品与质控品实测浓度高于赋值,校正量约为QMS/EVER的三分之一。

核心结论

  • ACMIA/EVRO与CE-IVD认证LC-MS/MS缺乏可互换性,而QMS/EVER与LC-MS/MS具有可互换性。
  • 研究者假设ACMIA/EVRO采用抗西罗莫司抗体,其校准品赋值校正不足,未能充分反映真实样本中依维莫司代谢物的交叉反应。

研究设计与样本

  • 研究纳入67例实体器官移植患者全血样本,其中肾移植31例、肝移植36例。
  • 每种检测方法使用单一批次试剂、校准品和质控品。
  • 采用Passing-Bablok回归和Bland-Altman差异图评估偏差与个体一致性,并用LC-MS/MS测定校准品和质控品实际浓度与赋值的差异。

主要发现

  • ACMIA/EVRO与LC-MS/MS比较:截距0.244 ng/mL(95%CI -0.254至0.651 ng/mL),斜率1.511(95%CI 1.420至1.619),合并偏差44.8%(95%CI 41.2至48.3%)。
  • QMS/EVER与LC-MS/MS比较:截距-0.151 ng/mL(95%CI -0.671至0.256 ng/mL),斜率0.971(95%CI 0.895至1.074),合并偏差-3.6%(95%CI -8.4至1.1%),无统计学显著性。
  • ACMIA/EVRO校准品和质控品实测浓度高于赋值,其校正量约为QMS/EVER校正量的三分之一。

关键数值与推荐

  • ACMIA/EVRO与LC-MS/MS:斜率1.511(95%CI 1.420至1.619),合并偏差44.8%(95%CI 41.2至48.3%)。
  • QMS/EVER与LC-MS/MS:斜率0.971(95%CI 0.895至1.074),合并偏差-3.6%(95%CI -8.4至1.1%)。

临床怎么用

  • 在实体器官移植患者依维莫司治疗药物监测中,QMS/EVER与LC-MS/MS结果可互换使用。
  • ACMIA/EVRO与LC-MS/MS结果不可互换,临床解读时应考虑方法学差异,避免直接比较或切换检测方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to evaluate the interchangeability between the Siemens Healthineers' "EVRO" new affinity chrome-mediated immunoassay (ACMIA/EVRO) and Thermo Fisher Scientific's "EVER" Quantitative Microsphere System (QMS/EVER) with Chromsystems' CE-IVD-certified "MassTox" liquid-chromatography/tandem-mass spectrometry (LC-MS/MS) assay for the therapeutic drug monitoring of everolimus. METHODS: A single lot of reagent, calibrators and controls were used for each assay. A total of 67 whole blood samples (n=67) from patients receiving solid organ transplant were analyzed (n=31 with kidney transplant and n=36 with liver transplant); Passing-Bablok regression and Bland-Altman difference plot were used to evaluate bias and individual agreement; LC-MS/MS analysis was used to measure the actual concentrations of calibrators and controls compared to the assigned value. RESULTS: ACMIA/EVRO did not show any systematic bias compared to LC-MS/MS (intercept=0.244 ng/mL, 95% CI: -0.254 to 0.651 ng/mL). Nevertheless, significant proportional bias (slope=1.511, 95% CI: 1.420 to 1.619) associated to a combined bias of 44.8% (95% CI: 41.2-48.3%) was observed. Conversely, QMS/EVER did not show any bias at both systematic (intercept=-0.151 ng/mL, 95% CI: -0.671 to 0.256 ng/mL) and proportional level (slope=0.971, 95% CI: 0.895 to 1.074) with a non-statistically significant combined bias of -3.6% (95% CI: -8.4-1.1%). Based on a concentration of calibrators and controls above the assigned value for both the analytical methods, in the ACMIA/EVRO a correction which was approximately one-third of the correction for the QMS/EVER was observed. CONCLUSIONS: ACMIA/EVRO but not QMS/EVER shows a lack of interchangeability with the CE-IVD-certified LC-MS/MS assay. We hypothesize that, as the ACMIA/EVRO uses an anti-sirolimus antibody, the under-corrected assigned value in the assay calibrators was not sufficient to reproduce the everolimus metabolites cross-reactivity occurring in real samples.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Ialongo C, D'alessandro A, Sapio M, et al. Evaluation of the interchangeability between the new fully-automated affinity chrome-mediated immunoassay (ACMIA) and the Quantitative Microsphere System (QMS) with a CE-IVD-certified LC-MS/MS assay for therapeutic drug monitoring of everolimus after solid organ transplantation. Clin Chem Lab Med. 2022. PMID: 36330751. doi:10.1515/cclm-2022-0699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。